Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Biliary02: Rilvegostomig or Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer
jRCT2031250495Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised trial of rilvegostomig in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoint: Overall Survival (PD-L1 ≥1% population). Started Feb 2026; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on jRCT2031250495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250495.